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Introduction
Lung cancer (non-small cell and small cell carcinomas) includes malignancies that arise within the lung parenchyma or bronchi. The pleural surface of the lungs gives rise to mesothelioma. Lung cancers are pathologically categorized into non-small cell and small cell carcinoma. Surgery, chemotherapy, and radiation therapy all play important roles in the treatment of lung cancer. There is an exciting and developing understanding of the wide variety of biologic characteristics and behaviors of lung cancers and new biologic and molecular tests have enabled clinicians to better tailor individualized treatment strategies.
Epidemiology
The American Cancer Society has estimated that in 2009, there were 219,440 new diagnoses of lung cancer and 159,390 deaths from the disease in the United States. Lung cancer is the second most common form of cancer in both men and women. It remains the most common cause of cancer-related death. Lung cancer incidence in the United States climbed throughout the 20 th century as tobacco smoking became increasingly popular. Rates of smoking among men began to fall in the 1960's and, beginning in the early 1990's, the incidence rate of lung cancer in men also began to fall. Rates of smoking among women were never as high as those in men. However, decline in smoking rates among women did not begin until the 1970's. The lung cancer incidence Citation: Gordon JA, Kurian E, Bedayat A, Akalin A, Uy K, Pieters RS. Lung Cancer and Mesothelioma. In: Pieters RS, Liebmann J, eds. Cancer Concepts: A Guidebook for the Non-Oncologist. Worcester, MA: University of Massachusetts Medical School; 2015.
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There are about 2500 cases of mesothelioma diagnosed each year in the United States. The Surveillance, Epidemiology, and End Results (SEER) data base reports that the incidence of mesothelioma peaked in the early 1990's, and has been gradually declining since. The peak and decline in mesothelioma incidence is believed to be due to the widespread use of asbestos in construction during the 20 th century. Since the early 1970's however, federal regulations have sharply limited the use of asbestos.
Etiology
In the United States and around the world, cigarette smoking is the strongest and most prevalent risk factor for the development of lung cancer. The risk is related not only to the amount of cigarette use (usually expressed as packs per day) but to the cumulative duration of such use (usually expressed as pack years). Cigarette use is estimated to account for approximately 90% of all lung cancers. Thus, it is a readily targeted life style risk factor. Second hand smoke exposure (and some people believe even third hand exposure from carcinogens that deposit on clothing) is a real risk factor, albeit nowhere near as significant as first hand exposure.
The role that genetics play in the etiology of lung cancer is not clear. There are people who develop lung cancer without any known cigarette use or other risk factors. In addition, not all people who smoke cigarettes develop lung cancer. There are some familial genetic syndromes, but these are not common.
In the last half century, the relative incidence of squamous cell carcinoma has fallen compared to adenocarcinoma. It is believed that this change in histology is in large part due to the wide-spread introduction of filtered cigarettes in the 1950's. Though the overall risk of lung cancer from filtered cigarettes is the same as from unfiltered cigarettes, filters alter the type of carcinogens and location of carcinogen deposition resulting from smoking. Filters force smokers to inhale more deeply, increasing the likelihood that carcinogens will be deposited deep in alveoli or terminal bronchioles. This altered pattern of carcinogen deposition has been hypothesized to be the reason why the usually peripherally-based adenocarcinomas have been increasing in frequency as compared to the usually centrally-based squamous cell carcinomas in the last two decades. Deeper inhalation also results in hotter and more complete combustion of the cigarette.
Risk factors for the development of mesothelioma include asbestos exposure and cigarette smoking. The combination of the two multiplies the risk. Shipyard workers, plumbers, construction-workers and asbestos miners were at significant risk of asbestos exposure. Occupational history is an important part of the workup for mesothelioma.
Screening
Recently, the National Lung Screening Trial (NLST) demonstrated decreased mortality in high risk patients (patients 55-74 years of age with a 30 pack-year smoking history who were currently smoking (or quit within the previous 15 years) who underwent low dose chest CT scan to screen for lung cancer. These results are encouraging and low dose radiation CT screening of patients at high risk for lung cancer has now been endorsed by a number of national organizations. However, associated harms include radiation exposure, false positive results, and unnecessary interventions (Figure 1 ). 
Recommendation
The United States Public Health Service Task Force on Prevention recommendations are summarized below:
• Asymptomatic adults aged 55 to 80 years who have at least a 30
pack-year smoking history and currently smoke or have quit smoking within the past 15 years. Screen annually for lung cancer with low-dose computed tomography. • Discontinue screening when the patient has not smoked for 15 years ( Figure 2 ). It is important to appreciate that the vast majority of lung nodules identified by CT screening are not cancer. The costs and risks to patients of evaluating many benign lung nodules will have to be weighed against potential benefits of screening for each patient. Additionally, the NLST was conducted in a limited number of centers with a well-defined protocol for evaluating lung nodules. Any screening program based on the NLST should incorporate the same rigorous standards that were used in the study.
Clinical Presentation
A majority of lung cancers are diagnosed at advanced stages. This is due in part to the limitations of screening for lung cancer and to lung cancer developing in a stealthy manner, often being asymptomatic at early stages of the disease. In addition, a number of presenting symptoms (cough, shortness of breath, weight loss, decreased appetite, and fatigue) are nonspecific and can be caused by a variety of other nonmalignant etiologies, most often pneumonia (Figures 3a & b) . 
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Mesothelioma
Mesothelioma (Figure 10a , b & c) is distinct from parenchymal lung cancer. It arises from the pleural surface that surrounds the lungs, whereas lung cancer arises from either the parenchymal tissues or the airways (although lung cancer can invade into or spread to the pleural surfaces). Three histologic types of malignant mesothelioma exist: epithelioid, sarcomatoid and biphasic (mixed epithelioid and sarcomatoid). 
Prognostic Factors, Staging and Natural History
Lung cancer is staged with the American Joint Committee on Cancer (AJCC) tumor, lymph node, and metastasis (TNM) system, seventh edition. As with all cancers, staging is based on prognostic grouping and predicted natural history of the disease. So stage is a measure of an individual patient's prognosis. The other important prognostic factor is the individual patient's overall condition, referred to as Performance Status.
Small cell lung cancer has a higher propensity to spread to distant parts of the body (metastasize) early in the course of the disease than does non-small cell lung cancer. However, any lung cancer can metastasize. The common anatomic locations for metastases include, but are not limited to, other parts of the lungs, regional lymph nodes, liver, adrenal glands ( Figure 11 ), brain ( Figure 12 ), and bones. Lung cancer can spread to the lymph nodes that are within and outside of the lungs, such as to the lung hilar areas, the mediastinum (the area in between the lungs), and to the supraclavicular regions (above the collar bones). Lung cancer can also grow by direct extension into nearby anatomic structures, such as the airways, the major blood vessels, the heart, and the chest wall. Mesothelioma has a lower tendency to metastasize than do most lung cancers. It is more apt to grow along the pleural surfaces and to extend directly into the lung parenchyma and the chest wall. It can also grow into the diaphragms, which sit underneath the lungs (Figures 13 & 14) . Both lung cancer and mesothelioma can cause pleural effusions, which are collections of fluid within the pleural space that separates the lungs from the chest walls. As this pleural fluid expands, it compresses the lungs, adversely affecting lung function (producing shortness of breath). Pericardial fluid can also develop within the space between the heart and its surrounding lining (the pericardium). As this pericardial effusion grows, it compresses the rhythmic contraction of the heart and thereby diminishes cardiac function. This is referred to as cardiac tamponade, which can be life threatening.
The presence of lymph node involvement by lung cancer (Figure 15 ) and the presence of any distant metastases are very important in staging lung cancer. The staging of lung cancer not only helps to identify appropriate treatment options, but also provides meaningful prognostic information as to the benefits of available therapies and prognosis. Nonsmall cell lung cancer is staged based on the role that surgery may have in its treatment: early stage (surgery has a role), locally advanced stage (surgery may or may not have a role), and advanced stage (surgery does not have a role except for palliation). Starting in 2010, small cell cancers are staged with the same system as non-small cell cancers. The current lung staging systems can be found at The American Joint Committee on Staging and the revised TNM Staging System.
Drawing a sketch of the extent of disease on a diagram of the body or the chest helps students learn staging systems and oncologists conceptualize the patient's disease to plan appropriate treatment. These staging diagrams make the staging systems much clearer to physicians, by illustrating the extent of disease often clarifying treatment decisions and assist in learning the AJCC staging system for each disease site.
An interactive series of staging diagrams are available here. Small cell lung cancer (Figures 16 & 17) now is staged with the same system as non-small cell cancer. The staging system previously used for this disease revolved around the role that radiation therapy could have in its treatment. If the extent of the tumor could be safely encompassed within a standard radiation field, then the small cell lung cancer was termed limited stage. Otherwise, the disease was called extensive stage, usually metastatic. This terminology is still found in older charts and academic papers, and in the minds of many oncologists. Figure 19 ). There is no standard serum blood test used to diagnose lung cancer or mesothelioma. A number of serum markers have been identified, such as carcinoembryonic antigen (CEA), but as of now, they are not routinely used to screen for or to diagnose lung cancer. The key to proper diagnosis remains obtaining adequate tissue through a biopsy or from an operation for detailed pathology testing. There is a developing array of molecular and histochemical tests being used to aid in the diagnosis of lung cancer and mesothelioma. Increasingly, some molecular tests are also affecting treatment choices. 
Principles of Treatment
A thorough history and physical examination are important to help identify the panoply of presenting problems and to identify any anatomic findings suggestive of cancer spread or anatomic compromise. Because most people who develop lung cancer have a cigarette smoking history, one needs to identify any other tobacco-related problems, such as coronary heart disease, diabetes mellitus, peripheral vascular disease, other cancers, emphysema, and central nervous problems (such as strokes). These medical issues can complicate and limit the treatment options available.
Surgery
For non-small cell lung cancer, surgical resection is the only reliable curative modality for patients who present at an early enough stage, which is unfortunately the minority. Lobectomy (Figures 20 and 21) is the surgery of choice for small to medium-sized tumors while pneumonectomy is done for larger or centrally located tumors. An operation treats only localized disease, so if there is a higher likelihood of systematic metastases, chemotherapy is added after surgery. This is the case after selected Stage 1B and all Stage 2 patients. For Stage 3 patients, there is a very high likelihood of systemic metastases in addition to extensive local disease so the foundation of treatment is a combination of radiation and chemotherapy, and in selected patients surgical resection is done afterwards to remove residual disease. The role of surgery in advanced or overtly metastatic disease is palliation, such as drainage of pleural effusion or relief of airway obstruction.
For small cell lung cancer, surgical resection is not standard and is done only for selected patients with tumors smaller than 2cms with no lymph node metastases, and either preceded or followed by chemotherapy because of the great tendency of small cell cancer to metastasize early. The only form of surgery acceptable for these patients is lobectomy. The currently preferred treatment method, however, even for these very early stage patients is combined chemoradiation.
When mesothelioma is removed surgically, an attempt is made to remove the entire pleural surface of the affected lung and the chest wall (pleurectomy-PL). Surgery that involves the removal of the ipsilateral pleura, the ipsilateral diaphragm and pericardium, the entire involved lung, and frequently part of the chest wall is called extra-pleural pneumonectomy (EPP) (Figure 25 ). The current standard method of attempting cure for mesothelioma involves administering chemotherapy first to eliminate possible metastases (neoadjuvant chemotherapy), EPP to remove the bulk of the tumor, and post-operative radiation to the ipsilateral hemithorax to attempt to eradicate residual disease. Many patients with mesothelioma do not have the cardiopulmonary reserve to tolerate an EPP, and even after undergoing this treatment regimen the recurrence rate is still high.
However, not every person with early stage non-small cell disease is medically able to withstand a major thoracotomy or the loss of lung parenchyma. Therefore cardiopulmonary and other medical assessment is appropriate before embarking on such major procedures. Pulmonary function tests are performed on major lung resection candidates, and predict the probability of major postoperative pulmonary-related complications. Regardless of the type of lung resection done (lobectomy, pneumonectomy etc.), patients should have at least 40% of their ideal FEV1 (forced expiratory volume in 1 second) and DLCO (diffusion capacity for carbon monoxide) left at the end of their lung surgery. Since major lung resections are quite stressful on the heart because of the acute increase in pulmonary vascular resistance which accompanies lung removal, in selected patients a cardiac evaluation in the form of either an exercise or pharmacologic cardiac stress test is done.
Some people decide they do not want surgery. It is not yet known to what degree patients may still be cured if they medically cannot tolerate or choose not to undergo an operation but receive other types of treatments, such as newer radiation therapy techniques that focally target the tumor with high doses (Movie 2). Even if such people cannot achieve a cure of their cancer, they may enjoy long term survival.
Chemotherapy
For localized small cell carcinoma, clinical studies over the years have shown that there is an improvement in clinical outcome, including survival, if limited stage small cell lung cancer is treated with a combination of chemotherapy and radiation therapy. This therapy needs to start as rapidly as possible.
When a non-small cell lung cancer has spread to nearby lymph nodes or has spread to other nearby anatomic structures (such as the chest wall) but has not overtly been found to have metastasized elsewhere, chemotherapy with radiation therapy can be used initially to treat the cancer. This is called neoadjuvant treatment. Some patients whose tumors respond well to concurrent chemotherapy and thoracic radiation may be candidates for thoracic surgery to remove any residual cancer. As the cancer becomes bulky, such neoadjuvant treatment is less and less successful.
When either non-small cell or small cell cancers have spread to distant sites (metastatic, or Stage IV disease), then the foundation of treatment is systemic chemotherapy. The goal of such treatment is palliative, not curative. Randomized trials have shown about a six to eight-month improvement in median overall survival with the use of current chemotherapy in metastatic lung cancer compared to no anti-cancer treatment. However, patients who respond to treatment can enjoy significant relief of symptoms caused by the cancer, such as pain, fatigue, shortness of breath, loss of appetite, and weight loss. It has recently been documented that early involvement of a palliative care service in the care of patients with advanced lung cancer can extend survival as well as enhance quality of life.
A small percentage of patients with non-small cell lung cancer, particularly with adenocarcinoma, may have a specific acquired gene mutation in their cancer that can serve as a target for therapy. Mutations in the epidermal growth factor receptor (EGFR) gene can cause activation of the EGFR tyrosine kinase (TK). Erlotinib and gefitinib are inhibitors of the EGFR TK and treatment with these drugs, will produce a tumor response in 75% of these patients. Similarly, the fusion gene, echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) results in activation of the ALK oncogene. Crizotinib is a specific inhibitor of ALK TK and can produce a tumor response in about 60% of patients whose tumors have the EML-ALK fusion gene.
Recently the antibodies nivolumab and pembrolizumab have been approved for treatment of recurrent metastatic non-small cell lung cancer after previous treatment with chemotherapy. These antibodies target the programmed death 1 (PD-1) receptor on T cells. PD-1 activation is one mechanism used by the immune system to down regulate an immune response. Anti-PD-1 antibodies are able to block this immune checkpoint and represent a novel immune therapy of lung cancer. It is anticipated that the use of these antibodies, and others that work via a similar mechanism, will increase significantly in the near future.
Radiation Therapy (RT)
Radiation therapy is regional treatment, used to treat the primary and draining lymphatic volumes, with curative intent (as primary treatment, hoping to achieve long term control), as neoadjuvant or adjuvant therapy (in each case, with or without sensitizing chemotherapy), with prophylactic intent or with palliative intent.
Recently, stereotactic radiation therapy (2-5 treatments) or radiosurgery (a single treatment) has been used in an attempt to ablate small tumors in the chest or the brain (Movie 2). In addition, fractionated radiation therapy is often utilized in an attempt to prevent the development of brain metastases in patients with small cell carcinoma, referred to as prophylactic cranial irradiation (PCI).
In the palliative treatment of advanced stages of lung cancer and mesothelioma, radiation therapy may be used to target a painful bone metastasis or to help keep open a lung airway that is becoming obstructed or compressed by the cancer. It is important to remember that when a patient reaches a point in the course of cancer that anti-cancer treatment is no longer possible, the responsibility to still care for the person remains. In particular, hemoptysis is effectively and quickly reduced or eliminated in patients receiving palliative radiotherapy.
Conclusion
Management of all forms of lung cancer and of mesothelioma requires a multidisciplinary approach to care involving Medical Oncologists, Radiation Oncologists, Thoracic Surgeons, Pulmonologists, Palliative Care Physicians, Pathologists, Radiologists, and Primary Care Physicians.
Prevention is the most effective means of decreasing mortality from these diseases; this requires protection from exposure to asbestos and tobacco. 
Staging Diagrams
AJCC staging consists of the disease (cancer site/type), the type of staging or timing of the staging: clinical (c) versus pathologic (p) versus post-neoadjuvant therapy (yp), the stage group (I-IV) and the T (primary site), N (nodal involvement), and M (metastasis) stage categories.
Oncologists draw tumor deposits on outlines of body regions, usually with red ink, during the staging of a cancer. The process of drawing helps physicians remember the patient's stage; drawing a series of stages for a given disease site helps learn the staging system, and makes the AJCC staging table meaningful for visual learners.
In this packet are:
1. Blank staging diagrams to assist with staging the patients you see. Printing out these blank diagrams and staging patients on the diagrams would be a valuable exercise.
2. Case-based interactive staging diagrams to provide a self-assessment of your staging knowledge. A patient's extent of disease is described in each case. Write the Type of Staging, Stage Group, T stage, N stage, and M stage in the corresponding blank fields. Clicking on the Expert Answers and Diagrams link will trigger the correct stage and annotated diagram to appear.
The blank diagrams below were created using a CT image set on the Varian Aria Radiation Therapy Treatment Planning System. Images Courtesy of University of Massachusetts Medical School, Department of Radiation Oncology.
